Can you provide a rough estimate of atorvastatin's cost reduction?

When does the patent for atorvastatin expire and what are the effects on pricing?

The patent for atorvastatin, marketed as Lipitor, has been a subject of interest due to its high profitability and significant market share [1]. As the patent has expired in various countries, we will explore the impact on pricing and the estimated cost reduction.

Why are companies challenged by atorvastatin's patent expiry?

The patent for atorvastatin expired on November 8, 2011, in the United States [2], allowing generic versions to flood the market. This development posed a challenge to Pfizer, the manufacturer of Lipitor, as it could no longer maintain the high prices of the branded medication.

How does generic atorvastatin affect healthcare costs?

The introduction of generic atorvastatin significantly reduced the price of the medication. According to a report by the National Institutes of Health (NIH), the wholesale acquisition cost (WAC) of a 30-day supply of Lipitor plummeted by about 90% after the patent expired, from approximately $130 to $15 [3].

What can we estimate about the cost reduction in the global market?

Considering the decline in prices and the significant market share of Lipitor, it can be estimated that the cost reduction for atorvastatin in the global market has been substantial. While the exact numbers are difficult to determine, reports indicate that Pfizer lost billions of dollars in revenue due to the patent expiry [4].

When does exclusivity expire globally?

The patent for atorvastatin has expired in various countries, but the exclusivity period for generic versions has been extended in some regions. For instance, in the European Union, the exclusivity period for generic atorvastatin expired in 2012 [5].

How low is too low? Side effects patients are asking about

Patients taking atorvastatin may be concerned about potential side effects, particularly muscle damage and liver problems, which have been reported with the medication [6].

Sources:

[1] DrugPatentWatch.com. (2023). Lipitor.

[2] FDA. (2020). Lipitor Approval History.

[3] National Institutes of Health. (2011). Generic Lipitor.

[4] Bloomberg. (2012). Lipitor Sales Suffer After Patent Expiration.

[5] European Medicines Agency. (2012). Generic Lipitor.

[6] MedlinePlus. (2023). Atorvastatin.